Recent development in electrochemical biosensors for cancer biomarkers detection

Hasan, Md. Rafiul; Ahommed, Md. Sohel; Daizy, M.; Bacchu, M.S.; Ali, M.R.; Al-Mamun, Md Rashid; Aly, Mohamed Aly Saad; Khan, M. Z. H.; Hossain, Syed Imdadul

doi:10.1016/j.biosx.2021.100075

Cited by 45 publications

(23 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of biosensors and nanotechnology is being tested to increase the sensitivity and specificity of detection. Biosensors are devices that detect a biomarker by a chemical process which is converted into an electric signal by a transducer, and the signal is then processed and amplified [ 113 ]. Moreover, gold nanoparticles, quantum dots, nanotubes, and nanoribbons provide a high surface-to-volume ratio, allowing different molecules (antibodies, linkers, small molecules, etc.)…”

Section: Techniques Used To Detect Molecular Cancer Biomarkersmentioning

confidence: 99%

Molecular Biomarkers in Cancer

2022

View full text Add to dashboard Cite

Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer, occurrence of cancer, or patient outcome. They may include germline or somatic genetic variants, epigenetic signatures, transcriptional changes, and proteomic signatures. These indicators are based on biomolecules, such as nucleic acids and proteins, that can be detected in samples obtained from tissues through tumor biopsy or, more easily and non-invasively, from blood (or serum or plasma), saliva, buccal swabs, stool, urine, etc. Detection technologies have advanced tremendously over the last decades, including techniques such as next-generation sequencing, nanotechnology, or methods to study circulating tumor DNA/RNA or exosomes. Clinical applications of biomarkers are extensive. They can be used as tools for cancer risk assessment, screening and early detection of cancer, accurate diagnosis, patient prognosis, prediction of response to therapy, and cancer surveillance and monitoring response. Therefore, they can help to optimize making decisions in clinical practice. Moreover, precision oncology is needed for newly developed targeted therapies, as they are functional only in patients with specific cancer genetic mutations, and biomarkers are the tools used for the identification of these subsets of patients. Improvement in the field of cancer biomarkers is, however, needed to overcome the scientific challenge of developing new biomarkers with greater sensitivity, specificity, and positive predictive value.

show abstract

Section: Techniques Used To Detect Molecular Cancer Biomarkersmentioning

confidence: 99%

Molecular Biomarkers in Cancer

2022

View full text Add to dashboard Cite

show abstract

“…Electrochemical miRNA biosensors with high sensitivity, high selectivity, and reliable reproducibility hold promise to multiplex detection. Besides, Hasan et al (2021) reviewed the application of electrochemical biosensors in cancer-related biomarkers detection.…”

Section: Introductionmentioning

confidence: 99%

Recent Progresses in Electrochemical DNA Biosensors for MicroRNA Detection

Zhang

Liu

et al. 2022

Phenomics

View full text Add to dashboard Cite

MicroRNAs (miRNAs), as the small, non-coding, evolutionary conserved, and post-transcriptional gene regulators of the genome, have been highly associated with various diseases such as cancers, viral infections, and cardiovascular diseases. Several techniques have been established to detect miRNAs, including northern blotting, real-time polymerase chain reaction (RT-PCR), and fluorescent microarray platform. However, it remains a significant challenge to develop sensitive, accurate, rapid, and cost-effective methods to detect miRNAs due to their short size, high similarity, and low abundance. The electrochemical biosensors exhibit tremendous potential in miRNA detection because they satisfy feature integration, portability, mass production, short response time, and minimal sample consumption. This article reviewed the working principles and signal amplification strategies of electrochemical DNA biosensors summarized the recent improvements. With the development of DNA nanotechnology, nanomaterials and biotechnology, electrochemical DNA biosensors of high sensitivity and specificity for microRNA detection will shortly be commercially accessible.

show abstract

“…Cancer has ranked as a leading cause of alarming global deaths, with 19.3 million reported cases and 10.0 million deaths in 2020 [ 1 ]. The majority of cancer deaths are caused by the metastasis of malignant cancer cells to other organs through blood and the lymphatic system, thus making it essential to detect cancers at early stages before they become incurable [ 2 ]. However, the conventional detection techniques, oncological imaging and biopsy–cytology of specimens, are not applicable to common screening due to their drawbacks such as being tedious, expensive, and harmful to the body.…”

Section: Introductionmentioning

confidence: 99%

Label-Free Immunosensor Based on Polyaniline-Loaded MXene and Gold-Decorated β-Cyclodextrin for Efficient Detection of Carcinoembryonic Antigen

2022

View full text Add to dashboard Cite

Multiple strategies have been employed to improve the performance of label-free immunosensors, among which building highly conductive interfaces and introducing suitable biocompatible carriers for immobilizing antibodies or antigens are believed to be efficient in most cases. Inspired by this, a label-free immunosensor for carcinoembryonic antigen (CEA) detection was constructed by assembling AuNPs and β-CD (Au-β-CD) on the surface of FTO modified with PANI-decorated f-MXene (MXene@PANI). Driven by the high electron conductivity of MXene@PANI and the excellent capability of Au-β-CD for antibody immobilization, the BSA/anti-CEA/Au-β-CD/MXene@PANI/FTO immunosensor exhibits balanced performance towards CEA detection, with a practical linear range of 0.5–350 ng/mL and a low detection limit of 0.0429 ng/mL. Meanwhile, the proposed sensor presents satisfying selectivity, repeatability, and stability, as well as feasibility in clinic serum samples. This work would enlighten the prospective research on the alternative strategies in constructing advanced immunosensors.

show abstract

Recent development in electrochemical biosensors for cancer biomarkers detection

Cited by 45 publications

References 79 publications

Molecular Biomarkers in Cancer

Molecular Biomarkers in Cancer

Recent Progresses in Electrochemical DNA Biosensors for MicroRNA Detection

Label-Free Immunosensor Based on Polyaniline-Loaded MXene and Gold-Decorated β-Cyclodextrin for Efficient Detection of Carcinoembryonic Antigen

Contact Info

Product

Resources

About